Dual-Action Marine Peptides Reverse HFD-Induced Obesity& Hepatic Steatosis: Clinically Validated Solutions for Metabolic HealthFormulations

Title:  

Dual-Action Marine Peptides Reverse HFD-Induced Obesity& Hepatic Steatosis: Clinically Validated Solutions for Metabolic HealthFormulations  

Blue Eyes Biotech Co., Ltd. unveils breakthrough researchon proprietary low-MW (<1kDa) marine peptides demonstrating unprecedenteddual efficacy against obesity and fatty liver in high-fat diet (HFD) models.Key outcomes from 12-week preclinical trials:

✅ 15.3% Body Weight Reduction vs. HFDcontrol (p<0.001)  

✅ 42% Hepatic Lipid Drop (Oil Red Ostaining)  

✅ Liver Protection Markers:  

   -ALT/AST ↓38%/41%  

   -Nrf2 activation ↑3.1x(antioxidant defense)  

   -SREBP-1c ↓59%(lipogenesis blockade)  

Mechanistic Superiority for Developers:  

1. Peptide-Specific Bioactivity:  

   -Targeted PPARα/FXR agonism(fat oxidation↑/bile acidregulation)  

   -AMPK-mediated autophagy flux restoration

2. Delivery Innovations:  

   -Enteric-coated granules (>85% ileal absorption)  

   -Phospholipid complexation for hepatocyte targeting  

Application-Optimized Formats:  

•Nutraceuticals:80% peptide purity powders/capsules for weight + liver health  

•FunctionalFoods: Debittered hydrolysates for protein-fortified beverages  

•Pharmaceuticals:cGMP peptides for NASH drug development  

Technical Differentiation:  

- Source Specificity: Wild-caught pelagicfish (sustainably harvested MSC-certified)

- Process Precision: Enzymatic hydrolysis +3-step ultrafiltration  

- Bioactivity Guarantee: Standardized to 5peptide markers (HPLC-MS)  

End-to-End Partnership:  

✓Species Selection: Non-allergenicfish/squid sources  

✓Clinical Translation: Dose-ranging data(250-1000mg/day)  

✓Scale Capability: 100g → 500kg/month (ISO 22000)  

Request Preclinical Dossier & SampleSpecifications:  

[email protected]  

Explore Marine Innovations:www.blueeyes-bio.com